PET/CT in oncology—a major advance

The concept of hardware fusion between positron emission tomography (PET) and computed tomography (CT) has only been introduced commercially in the last 4 years. The advantages of this combined technique over PET alone have become obvious. There is increasing evidence to suggest that PET/CT adds com...

Full description

Saved in:
Bibliographic Details
Published inClinical radiology Vol. 60; no. 11; pp. 1143 - 1155
Main Authors Wechalekar, K., Sharma, B., Cook, G.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.11.2005
Subjects
18F-fluorodeoxyglucose
Fluorodeoxyglucose F18
Humans
Image Interpretation, Computer-Assisted - methods
Neoplasms - diagnostic imaging
Oncology
Positron emission tomography/computed tomography (PET/CT)
Positron-Emission Tomography - methods
Radiopharmaceuticals
Sensitivity and Specificity
Tomography, X-Ray Computed - methods
18F-fluorodeoxyglucose
Positron emission tomography/computed tomography (PET/CT)
Oncology
Online AccessGet full text

Cover

More Information
Summary:The concept of hardware fusion between positron emission tomography (PET) and computed tomography (CT) has only been introduced commercially in the last 4 years. The advantages of this combined technique over PET alone have become obvious. There is increasing evidence to suggest that PET/CT adds complementary information in staging, re-staging and follow-up in oncology patients, leading to changes in management plans. The present paper is a review of the strengths, weaknesses, current evidence and future directions of this technique.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:0009-9260
1365-229X
DOI:10.1016/j.crad.2005.05.018